ArticleStem cell research & therapy2026
Platelet-released growth factors promote pro-angiogenic effects in endothelial cells: a translational perspective on wound healing and regenerative medicine.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-Released Growth Factors (PRGF) are a standardized, cell- and fibrin-free platelet lysate with translational potential for tissue repair. PRGF enhance tissue regeneration, particularly in contexts where angiogenesis is critical for restoring perfusion in chronic and non-healing wounds. Here, we present the first in vitro study demonstrating that PRGF exert pro-angiogenic effects at a working concentration of 10%. The study employs an endothelial cell-based model integrating targeted gene expression analysis, array-based profiling of angiogenesis-related proteins, and functional endothelial tube formation assays. In this setting, screening-level transcriptional and proteomic profiling indicated higher transcript levels of angiogenesis-related genes and increased signals of representative angiogenesis-associated mediators (e.g., Platelet Factor 4, Angiopoietin-1, Angiogenin) following PRGF stimulation. Functional tube formation assays demonstrated significant enhancement of multiple pro-angiogenic parameters in response to PRGF, including number of pieces (P < 0.001), junctions (P < 0.01), and segments (P < 0.05). These findings suggest that 10% PRGF may support angiogenesis and tissue regeneration and provide a foundation for further validation in more complex multicellular systems and in vivo models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.